Clinical Trial Update: Low-dose Baricitinib Plus Danazol for Steroid-resistant/Relapse Immune Thrombocytopenia [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating low-dose baricitinib plus danazol for steroid-resistant or relapsed immune thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• Baricitinib (baricitinib)
• Danazol (danazol)

Snippet

Sponsor: Peking University People's Hospital | Conditions: Immune Thrombocytopenia | Phase 2 | Status: UNKNOWN